Baptist Healthcare System, INC.
Baptist Healthcare System, INC. was paid $58.51M by Medicaid between Jan 2018 and Dec 2024, across 341 billing codes. Its largest line is 99283, emergency room visit (moderate) — 20% of everything it billed.
33Billing provider infoBAPTIST HEALTHCARE SYSTEM, INC.
RICHMOND, KY 40475
RICHMOND, KY 40475
33aNPI1568452290assigned 10/25/2005
33bProvider typeLegal Medicine
28Total paid$58.51M
24GClaims1,065,942
24DCodes billed341
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Legal Medicine providers in Kentucky
Rank by total paid#1 of 6
Median peer was paid$173K
This provider vs. median339×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official CARRICO, RICHARD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 134,229 | $8.39M | |
| 2019 | 131,942 | $7.60M | |
| 2020 | 127,163 | $6.32M | |
| 2021 | 157,973 | $7.58M | |
| 2022 | 166,195 | $8.83M | |
| 2023 | 182,673 | $9.86M | |
| 2024incomplete | 165,767 | $9.93M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 63,384 | 54,550 | $11.93M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.8% | 22,686 | 19,181 | $5.72M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.5% | 8,693 | 7,721 | $3.82M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.9% | 5,996 | 5,282 | $2.27M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.5% | 6,348 | 5,237 | $2.08M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.8% | 3,963 | 2,792 | $1.64M |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 2.5% | 6,333 | 5,990 | $1.45M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.4% | 7,157 | 5,843 | $1.42M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.2% | 13,044 | 6,038 | $1.30M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 2.1% | 3,073 | 1,534 | $1.21M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 2.1% | 2,442 | 1,873 | $1.20M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.9% | 9,195 | 8,364 | $1.09M |
329 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 19,174 | $919K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.5% | 36,352 | $904K |
| G0378 | Hospital observation service, per hour | 1.5% | 1,924 | $866K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.4% | 25,517 | $831K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 11,910 | $764K |
| 80053 | Comprehensive metabolic panel | 1.2% | 69,537 | $686K |
| 59025 | Fetal non-stress test | 1.1% | 5,754 | $617K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,240 | $579K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,189 | $520K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 14,813 | $512K |
| 71045 | Radiologic examination, chest; single view | <1% | 16,646 | $499K |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | <1% | 1,836 | $426K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 58,772 | $409K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 7,439 | $395K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 5,318 | $374K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,868 | $373K |
| 93971 | <1% | 1,900 | $368K | |
| 73630 | <1% | 3,455 | $345K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,609 | $345K |
| 36415 | Collection of venous blood by venipuncture | <1% | 76,525 | $341K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,150 | $328K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,572 | $319K |
| 73562 | <1% | 3,477 | $318K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 950 | $312K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,063 | $308K |
| 71250 | <1% | 2,028 | $285K | |
| 73610 | <1% | 2,977 | $277K | |
| 74018 | <1% | 3,661 | $262K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 337 | $259K |
| 73130 | <1% | 2,662 | $252K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 721 | $244K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,195 | $226K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,469 | $226K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,409 | $224K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,408 | $215K |
| 73030 | <1% | 2,698 | $212K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 1,403 | $211K |
| 72131 | <1% | 914 | $199K | |
| 84484 | <1% | 18,637 | $185K | |
| 73110 | <1% | 1,815 | $178K | |
| 96376 | <1% | 3,711 | $178K | |
| 72100 | <1% | 2,100 | $171K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 608 | $167K |
| 76775 | <1% | 967 | $167K | |
| 83880 | <1% | 4,954 | $150K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 17,047 | $148K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,528 | $136K |
| 96367 | <1% | 1,789 | $136K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 313 | $136K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,818 | $134K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,292 | $127K |
| 80306 | <1% | 8,055 | $125K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,259 | $121K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 151 | $120K |
| 78227 | <1% | 364 | $116K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,154 | $109K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 68 | $109K |
| 80050 | General health panel | <1% | 2,853 | $107K |
| 87507 | <1% | 389 | $100K | |
| 47563 | <1% | 75 | $100K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,673 | $99K |
| 81025 | <1% | 17,002 | $95K | |
| 76536 | <1% | 1,023 | $95K | |
| 83690 | <1% | 16,093 | $93K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,264 | $90K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 11,172 | $89K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 1,434 | $86K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,469 | $81K |
| 82805 | <1% | 1,720 | $80K | |
| 73502 | <1% | 1,271 | $77K | |
| 76830 | Ultrasound, transvaginal | <1% | 811 | $77K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,385 | $77K |
| 12001 | <1% | 737 | $75K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 218 | $71K |
| 81001 | <1% | 21,890 | $71K | |
| J3490 | Unclassified drugs | <1% | 628 | $68K |
| 10060 | <1% | 206 | $65K | |
| 76642 | <1% | 611 | $65K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,195 | $63K |
| 87522 | Neg quan hep c or qual rna | <1% | 1,652 | $61K |
| 70486 | <1% | 266 | $60K | |
| 84702 | <1% | 4,232 | $60K | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 394 | $59K |
| J2704 | Injection, propofol, 10 mg | <1% | 13,591 | $59K |
| 84145 | <1% | 2,935 | $59K | |
| 80061 | Lipid panel | <1% | 4,823 | $56K |
| 73221 | <1% | 200 | $56K | |
| 87081 | <1% | 7,286 | $55K | |
| 71271 | <1% | 871 | $53K | |
| 72040 | <1% | 529 | $52K | |
| 73080 | <1% | 641 | $51K | |
| 83735 | <1% | 8,815 | $51K | |
| 85027 | <1% | 8,249 | $48K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 677 | $47K |
| 72141 | <1% | 139 | $46K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,023 | $45K |
| 83605 | <1% | 5,068 | $43K | |
| 73590 | <1% | 535 | $43K | |
| 82077 | <1% | 3,215 | $42K | |
| 82607 | <1% | 2,933 | $40K | |
| 0097U | <1% | 171 | $40K | |
| 73090 | <1% | 437 | $38K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,250 | $38K |
| C1769 | Guide wire | <1% | 303 | $38K |
| 72070 | <1% | 359 | $37K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,376 | $37K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,236 | $36K |
| 72110 | <1% | 199 | $36K | |
| 81003 | <1% | 14,612 | $34K | |
| 80143 | <1% | 1,768 | $33K | |
| V2632 | Posterior chamber intraocular lens | <1% | 288 | $33K |
| 82728 | <1% | 2,531 | $32K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,189 | $31K |
| 90715 | <1% | 885 | $31K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,234 | $31K |
| 64615 | <1% | 142 | $30K | |
| 84439 | <1% | 3,250 | $30K | |
| 87902 | <1% | 155 | $29K | |
| 77066 | Tomosynthesis, mammo | <1% | 394 | $29K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 43 | $29K |
| 70496 | <1% | 87 | $28K | |
| 85379 | <1% | 3,193 | $28K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 388 | $27K |
| 87040 | <1% | 3,273 | $27K | |
| 0001A | <1% | 1,154 | $27K | |
| 80074 | <1% | 659 | $26K | |
| 0002A | <1% | 1,028 | $26K | |
| 80179 | <1% | 1,709 | $26K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,561 | $25K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,246 | $23K |
| 87186 | <1% | 2,945 | $22K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,745 | $22K |
| 82962 | <1% | 7,478 | $22K | |
| 95806 | <1% | 154 | $22K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 16,728 | $21K |
| 84466 | <1% | 1,974 | $20K | |
| 81002 | <1% | 4,465 | $20K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,020 | $20K |
| 86140 | <1% | 4,680 | $20K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 248 | $19K |
| 85610 | <1% | 4,939 | $19K | |
| 95811 | <1% | 28 | $18K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 26 | $17K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 20,786 | $17K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 528 | $16K |
| 84703 | <1% | 2,458 | $16K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,068 | $16K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,153 | $16K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,591 | $16K |
| 84112 | <1% | 174 | $15K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,308 | $15K |
| 83540 | <1% | 2,714 | $15K | |
| 96415 | <1% | 83 | $15K | |
| 36600 | <1% | 715 | $15K | |
| 82948 | <1% | 2,689 | $15K | |
| 72128 | <1% | 91 | $14K | |
| 87077 | <1% | 1,676 | $14K | |
| 82746 | <1% | 1,152 | $14K | |
| 82784 | <1% | 1,475 | $14K | |
| 0099U | <1% | 93 | $13K | |
| 84403 | <1% | 608 | $12K | |
| 86803 | <1% | 1,070 | $12K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,751 | $12K |
| 85730 | <1% | 1,800 | $12K | |
| 83516 | <1% | 959 | $11K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,749 | $11K |
| 86850 | <1% | 1,425 | $11K | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 120 | $11K |
| 93017 | <1% | 29 | $11K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 145 | $11K |
| 58558 | <1% | 22 | $10K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,849 | $10K |
| 86900 | <1% | 3,165 | $10K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 28 | $10K |
| 86901 | <1% | 3,090 | $10K | |
| 82375 | <1% | 962 | $10K | |
| 86038 | <1% | 992 | $10K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,729 | $9K |
| 74178 | <1% | 15 | $9K | |
| J2805 | Injection, sincalide, 5 micrograms | <1% | 85 | $9K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,971 | $9K |
| 71101 | <1% | 84 | $8K | |
| 87147 | <1% | 870 | $8K | |
| 87807 | <1% | 632 | $8K | |
| 93970 | <1% | 42 | $8K | |
| 70498 | <1% | 35 | $8K | |
| 86704 | <1% | 801 | $8K | |
| 74300 | <1% | 89 | $8K | |
| 82670 | <1% | 265 | $8K | |
| 84402 | <1% | 362 | $7K | |
| 73120 | <1% | 39 | $7K | |
| 87070 | <1% | 1,057 | $7K | |
| 87340 | <1% | 914 | $7K | |
| 86708 | <1% | 740 | $7K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,267 | $7K |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,251 | $6K |
| 82550 | <1% | 962 | $6K | |
| 86364 | <1% | 675 | $6K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,028 | $6K |
| 76641 | <1% | 61 | $6K | |
| 43249 | <1% | 15 | $5K | |
| 76870 | <1% | 58 | $5K | |
| 70491 | <1% | 14 | $5K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 43 | $5K |
| 87899 | <1% | 371 | $5K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 400 | $4K |
| 83050 | <1% | 800 | $4K | |
| 84550 | <1% | 739 | $4K | |
| 83993 | <1% | 233 | $4K | |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 328 | $4K |
| 85651 | <1% | 1,205 | $4K | |
| 86706 | <1% | 481 | $4K | |
| 81596 | <1% | 81 | $4K | |
| 82570 | <1% | 675 | $4K | |
| 12011 | <1% | 40 | $4K | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 1,422 | $4K |
| 85652 | <1% | 1,535 | $4K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,823 | $4K |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 1,583 | $4K |
| 95800 | <1% | 20 | $3K | |
| 76801 | <1% | 32 | $3K | |
| 83550 | <1% | 360 | $3K | |
| C1726 | Catheter, balloon dilatation, non-vascular | <1% | 13 | $3K |
| 96368 | <1% | 32 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,945 | $3K |
| 87205 | <1% | 813 | $3K | |
| 93880 | <1% | 12 | $3K | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 447 | $3K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,043 | $3K |
| 77080 | <1% | 49 | $3K | |
| 86003 | <1% | 27 | $3K | |
| 84100 | <1% | 605 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 226 | $3K |
| 94010 | <1% | 37 | $3K | |
| 29125 | <1% | 26 | $2K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 13 | $2K |
| 82172 | <1% | 93 | $2K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 370 | $2K |
| 83921 | <1% | 134 | $2K | |
| 86480 | <1% | 39 | $2K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,095 | $2K |
| 80069 | <1% | 284 | $2K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 578 | $2K |
| 82103 | <1% | 104 | $2K | |
| 73140 | <1% | 33 | $2K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 27 | $2K |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 443 | $2K |
| 82653 | <1% | 56 | $2K | |
| 94060 | <1% | 14 | $2K | |
| 0012A | <1% | 99 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,028 | $2K |
| 12002 | <1% | 15 | $2K | |
| 82977 | <1% | 304 | $2K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 120 | $2K |
| 83010 | <1% | 165 | $2K | |
| 94726 | <1% | 42 | $2K | |
| 73552 | <1% | 15 | $1K | |
| 84156 | <1% | 410 | $1K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,179 | $1K |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 433 | $1K |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 161 | $1K |
| 83883 | <1% | 114 | $1K | |
| 83001 | <1% | 88 | $1K | |
| 74019 | <1% | 14 | $1K | |
| 94729 | <1% | 36 | $1K | |
| 87088 | <1% | 172 | $1K | |
| 81374 | <1% | 12 | $1K | |
| 0011A | <1% | 103 | $1K | |
| 77065 | Tomosynthesis, mammo | <1% | 16 | $1K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 80 | $1K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 276 | $1K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,841 | $997.86 |
| 99152 | <1% | 14 | $944.88 | |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | <1% | 236 | $918.63 |
| 83615 | <1% | 159 | $797.66 | |
| 97802 | <1% | 73 | $797.40 | |
| 84146 | <1% | 42 | $679.95 | |
| 72170 | <1% | 23 | $668.73 | |
| 82104 | <1% | 40 | $630.75 | |
| C1758 | Catheter, ureteral | <1% | 13 | $604.26 |
| 83002 | <1% | 42 | $592.64 | |
| G0008 | Administration of influenza virus vaccine | <1% | 15 | $585.47 |
| 97803 | <1% | 41 | $577.36 | |
| 84153 | <1% | 29 | $523.96 | |
| 36591 | <1% | 19 | $519.34 | |
| 86592 | <1% | 151 | $500.83 | |
| 82785 | <1% | 12 | $495.76 | |
| 86308 | <1% | 78 | $432.64 | |
| 82820 | <1% | 47 | $413.09 | |
| 87493 | <1% | 32 | $409.97 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 260 | $409.82 |
| 85014 | <1% | 175 | $370.78 | |
| 86381 | <1% | 24 | $364.09 | |
| 86431 | <1% | 82 | $352.80 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 35 | $347.48 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 12 | $341.38 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 13 | $333.31 |
| 84478 | <1% | 70 | $312.02 | |
| 82465 | <1% | 43 | $305.84 | |
| 82248 | <1% | 73 | $274.65 | |
| 84425 | <1% | 13 | $272.80 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 46 | $271.44 |
| 84144 | <1% | 15 | $256.44 | |
| 84436 | <1% | 40 | $228.72 | |
| 85018 | <1% | 98 | $223.18 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 72 | $195.93 |
| 87220 | <1% | 42 | $176.26 | |
| 99499 | <1% | 48 | $175.00 | |
| 84481 | <1% | 14 | $166.86 | |
| 86709 | <1% | 15 | $162.63 | |
| 82272 | <1% | 50 | $157.12 | |
| 82565 | <1% | 18 | $156.30 | |
| 84480 | <1% | 15 | $155.98 | |
| Q3014 | Telehealth originating site facility fee | <1% | 25 | $132.38 |
| 90686 | <1% | 15 | $127.81 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 560 | $125.37 |
| 86015 | <1% | 12 | $123.47 | |
| 85007 | <1% | 44 | $118.86 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 18 | $110.43 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 12 | $93.76 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 147 | $87.12 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 37 | $75.66 |
| 80076 | <1% | 13 | $65.36 | |
| 82043 | <1% | 12 | $63.58 | |
| 87210 | <1% | 12 | $58.00 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 23 | $35.13 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 12 | $31.07 |
| J1597 | Injection, glycopyrrolate (glyrx-pf), 0.1 mg | <1% | 59 | $29.95 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 12 | $13.54 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCARRICO, RICHARD (CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.